Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 2
2(50.0%)
Phase 1
2(50.0%)
4Total
Phase 2(2)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05103345Phase 1Recruiting

Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor

Role: collaborator

NCT04182490Phase 2Completed

LMN-101 in a Campylobacter Human Challenge Model

Role: collaborator

NCT04150250Phase 2Completed

Cholera Anti-Secretory Treatment Trial

Role: collaborator

NCT04007263Phase 1Completed

A Multiple Ascending Dose Study of Safety and Pharmacokinetics of NP10679 in Normal Healthy Volunteers

Role: collaborator

All 4 trials loaded